Canopy Growth (CGC) Projected to Post Quarterly Earnings on Friday

Canopy Growth (NASDAQ:CGC) is projected to issue its Q3 2026 results before the market opens on Friday, February 6th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $70.9570 million for the quarter. Interested persons may visit the the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Friday, February 6, 2026 at 10:00 AM ET.

Canopy Growth (NASDAQ:CGC) last released its quarterly earnings results on Friday, November 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.10. The business had revenue of $47.86 million during the quarter, compared to analyst estimates of $71.82 million. Canopy Growth had a negative return on equity of 61.97% and a negative net margin of 113.21%. On average, analysts expect Canopy Growth to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Canopy Growth Stock Performance

CGC opened at $1.11 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 5.50 and a quick ratio of 4.23. Canopy Growth has a 1-year low of $0.77 and a 1-year high of $2.90. The company has a 50 day simple moving average of $1.25 and a two-hundred day simple moving average of $1.29. The firm has a market cap of $408.99 million, a P/E ratio of -0.57 and a beta of 0.43.

Institutional Trading of Canopy Growth

Several institutional investors and hedge funds have recently modified their holdings of the stock. Millennium Management LLC increased its stake in shares of Canopy Growth by 196.9% during the third quarter. Millennium Management LLC now owns 3,137,696 shares of the company’s stock valued at $4,579,000 after buying an additional 2,080,994 shares during the period. Two Sigma Investments LP bought a new position in shares of Canopy Growth during the 3rd quarter worth approximately $1,767,000. Tidal Investments LLC increased its position in shares of Canopy Growth by 31.5% during the second quarter. Tidal Investments LLC now owns 5,033,793 shares of the company’s stock worth $6,141,000 after purchasing an additional 1,204,530 shares in the last quarter. Jones Financial Companies Lllp increased its position in Canopy Growth by 10,308.3% during the 1st quarter. Jones Financial Companies Lllp now owns 969,533 shares of the company’s stock valued at $882,000 after buying an additional 960,218 shares in the last quarter. Finally, Murchinson Ltd. purchased a new position in shares of Canopy Growth in the second quarter worth $183,000. Institutional investors own 3.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on CGC shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Canopy Growth in a research note on Wednesday, January 21st. Alliance Global Partners reissued a “neutral” rating on shares of Canopy Growth in a report on Monday, December 15th. Benchmark upgraded Canopy Growth from a “sell” rating to a “hold” rating in a report on Monday, November 10th. Finally, Wall Street Zen raised Canopy Growth from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Three research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Canopy Growth currently has a consensus rating of “Reduce”.

About Canopy Growth

Canopy Growth Corporation is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets.

The company operates through multiple subsidiaries, including Tweed Inc, Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments.